Related Experiment Video
Updated: Jun 5, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Identification of Compound Heterozygous CYP11A1 Variants via Reanalysis of Clinical Sequencing Data
Ana Acosta Bedón1,2, Vahid Akbari3, Ralph Rothstein2,4
1Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
None:
A molecular diagnosis is currently achievable in approximately 50% of patients assessed by clinical geneticists at tertiary care centres. Next-Generation Sequencing Panels contain a defined group of genes associated with a clinically defined set of phenotypes. Most clinical sequencing providers streamline their wet-bench workflows by sequencing the entire exome or genome, followed by targeted bioinformatic extraction of variant data from a pre-specified gene set. Thus, additional data on these patients remain available but are only reviewed by special request. We interrogated clinical-grade sequencing data on two out of three affected members of a family with childhood-onset adrenal insufficiency in whom an autosomal recessive condition was suspected. Review of clinome data identified heterozygosity for CYP11A1 variants c.644T>C; p.(Phe215Ser) and c.1187G>A; p.(Arg396Lys) in both affected sibs. Long-read whole genome sequencing of the proband showed these variants were in trans, confirming compound heterozygosity and resolving the molecular etiology of the clinical diagnosis.
More Related Videos
Related Concept Videos
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenomics: Identification of New Drug Targets

